Supporting the journey to a cure
HCU Network Australia is driven by our vision: to be a driving force in the journey to a cure, improving quality of life along the way. Our journey is supported by companies who provide support or pro-bono services. You can read about our supporters below.
To enquire about sponsorship and how to partner with us, please contact HCU Network Australia.
Recordati Rare Diseases Australia, along with our sister company, Orphan Europe, is part of the Recordati Group, an international pharmaceutical company committed to providing orphan therapies to underserved rare disease communities globally.
Our mission is to improve the lives of people affected by rare diseases by developing and providing innovative and high-impact treatments. We are committed to increasing awareness and improving diagnosis for people with rare diseases.
Recordati Rare Diseases has partnerships with several patient support organisations and is dedicated to providing support and assistance to patients and families affected by rare diseases, as well as promoting education and research.
Orphan Technologies is dedicated to developing novel therapies to dramatically improve the lives of patients suffering from rare disorders. OT-58, our lead drug development candidate, has been optimized as an enzyme replacement therapy for classical homocystinuria, a genetic disease characterized by debilitating cardiovascular, skeletal, neurologic, and ophthalmologic complications. OT-58 is designed to reduce homocysteine levels via a targeted mechanism of action and may have therapeutic applications in other diseases. For more information, please visit www.orphantechnologies.com.
OT-58, Orphan Technologies’ lead drug candidate, is a modified recombinant enzyme replacement therapy in development as an enzyme replacement therapy for patients suffering from the rare disease classical homocystinuria. Classical homocystinuria is a genetic metabolic disease caused by a deficiency in the CBS enzyme leading to elevated levels of the amino acid homocysteine. OT-58 has consistently demonstrated significant reductions in homocysteine levels across multiple models of homocystinuria and has the potential to improve metabolic control, reduce or remove dietary restrictions, and positively impact clinical outcomes. OT-58 is anticipated to enter clinical evaluation in 2018 and has been granted Orphan Status by the US Food and Drug Administration and EMA. In addition, based on its mechanism of action, OT-58 has therapeutic potential in other diseases.
Morrison Homes are a passionate group of professionals, dedicated to building luxury homes. Our hands-on approach throughout the design and construction process ensures that, as a client, you are always satisfied, kept up-to-date and well informed. Our homes are constructed from the highest quality products, utilising the latest technologies.
We thank the following companies for pro-bono accounting and legal services.
At Robertson & Greenwood we believe in providing prompt, personalised service coupled with the highest levels of professional expertise. We specialise in working closely with our clients to help them achieve their business and wealth creation goals.
For much of our 119 year history, Carroll & O’Dea Lawyers has worked closely with some of Australia’s most well known community organisations and associations. It’s a strong part of who we are as a firm and an enduring part of our legacy. We can provide expert legal advice and skills needed by any type of community organisation, charity or association, from establishment and governance through to Estate Planning, Disputes and Employment. Carroll & O’Dea Lawyers, help organisations across the spectrum every day get on with their important work of contributing to and helping shape our society.